Non-Tuberculous Mycobacterial (NTM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 Non-Tuberculous Mycobacterial (NTM) are bacteria that are normally present in the environment. Inhalation of these bacteria may cause disease in both healthy patients and those with compromised immune systems. NTM disease most often affects the lungs in adults, but it may also affect any body site. Chronic pulmonary disease is the most common localized clinical manifestation of NTM. Mycobacterium avium complex, followed by M. kansasii, is the most frequent pathogen causing lung disease in the United States. Other pathogens occasionally causing pulmonary disease include M. abscessus, M. fortuitum, M. szulgai, M. simiae, M xenopi, M. malmoense, M. celatum, M. asiaticum, and M. shimodii. Except for patients with cystic fibrosis, children rarely develop this form of NTM disease, Although some NTM patients have a history of underlying chronic lung disease. The interpretation of NTM in the sputum of HIV-positive patients presents a particular problem, as these patients are frequently infected with NTM without evidence of pulmonary disease.

·       The overall average annual age-adjusted prevalence rate rose from 8.7 to 13.9 per 100,000 persons between the beginning and end of the surveillance period. The number of cases and case rate in the 50 to 80+ year age group was higher than in the 0–49-year age group. The age group that had the lowest average case rate was the 0–39-year age group, at 3 to 6 cases per 100,000 population.

·       The pulmonary region (59%) was the most frequently reported site of disease followed by skin or soft tissue, bone or joints, and others parts of the body.

Thelansis’s “Non-Tuberculous Mycobacterial (NTM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Tuberculous Mycobacterial (NTM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Non-Tuberculous Mycobacterial (NTM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Non-Tuberculous Mycobacterial (NTM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Non-Tuberculous Mycobacterial (NTM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032